Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Operating Expenses (2016 - 2025)

Adma Biologics (ADMA) has disclosed Operating Expenses for 13 consecutive years, with $26.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 4.21% year-over-year to $26.1 million, compared with a TTM value of $101.3 million through Dec 2025, up 25.76%, and an annual FY2025 reading of $101.3 million, up 25.76% over the prior year.
  • Operating Expenses was $26.1 million for Q4 2025 at Adma Biologics, up from $24.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $26.2 million in Q1 2025 and bottomed at -$40.2 million in Q4 2021.
  • Average Operating Expenses over 5 years is $16.3 million, with a median of $17.8 million recorded in 2023.
  • The sharpest move saw Operating Expenses crashed 50.16% in 2021, then skyrocketed 150.34% in 2022.
  • Year by year, Operating Expenses stood at -$40.2 million in 2021, then surged by 150.34% to $20.2 million in 2022, then decreased by 16.72% to $16.9 million in 2023, then soared by 48.4% to $25.0 million in 2024, then increased by 4.21% to $26.1 million in 2025.
  • Business Quant data shows Operating Expenses for ADMA at $26.1 million in Q4 2025, $24.6 million in Q3 2025, and $24.4 million in Q2 2025.